AZD7687 Multiple Ascending Dose Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD7687 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses

NCT01469923

Obesity

TERMINATED PHASE1

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329

NCT01207089

Overweight Healthy Male

COMPLETED PHASE1

Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687

NCT01217905

Type 2 Diabetes Obesity

COMPLETED PHASE1

Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

NCT03435276

Healthy Volunteers

COMPLETED PHASE1

AZD5423 Multiple Ascending Dose Study

NCT01037504

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight Obese

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

AZD7687

Intervention Type DRUG

Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.

2

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral suspension, once daily. Totally 8 doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD7687

Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.

Intervention Type DRUG

Placebo

Oral suspension, once daily. Totally 8 doses

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of signed and dated, written informed consent prior to any study specific procedures
* suitable veins for cannulation or repeated venepuncture.
* Have a body mass index (BMI) between 27 and 35 kg/m2

Exclusion Criteria

* Fasting serum (S)-glucose ≥7.0 mmol/L or non-fasting S-glucose ≥11.1 mmol/L at screening.
* Any eating disorder or actively attempting to loose weight within 3 months prior to enrolment.
* Smoking more than 7 cigarettes per week from time of consent

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes